In an era where regulatory scrutiny is on the rise, third-party audits have become indispensable in verifying that pharmaceutical excipients meet current Good Manufacturing Practices (cGMP). As the landscape of pharmaceutical manufacturing evolves, the responsibility of ensuring that raw materials adhere to stringent safety and quality standards increasingly falls upon the pharmaceutical companies themselves.
The Growing Demand for Quality Assurance
Pharmaceutical companies are under mounting pressure to guarantee that all components of their products, including excipients, are sourced from credible suppliers and manufactured according to best practices. The trend of outsourcing manufacturing has not diminished this obligation; instead, it has amplified the need for thorough inspections and audits. This shift in responsibility necessitates a more rigorous approach to quality assurance, particularly as the industry navigates complex regulatory environments.
Supplier Audits: A Daunting Challenge
As pharmaceutical companies intensify their focus on supplier audits, excipient suppliers face an escalating number of requests for on-site evaluations. Traditionally, these audits were infrequent and brief, occurring every three to five years and lasting only a day. However, as cGMP standards grow more rigorous, it has become increasingly difficult to conduct comprehensive audits in such a limited timeframe. Many audits have become hurried, risking the thoroughness and reliability of the assessment.
To address these challenges, pharmaceutical companies are now demanding longer audits—often extending to one or two days. However, this presents a new set of challenges, as these audits are resource-intensive, involving significant travel and accommodation costs for the auditing teams. Additionally, the burden on suppliers—who may not have the capacity to accommodate frequent audits—raises concerns about the feasibility and fairness of the process.
The Rise of Third-Party Certification
To alleviate the audit burden and ensure consistent quality, stakeholders across the pharmaceutical industry have come together to establish voluntary consensus standards for excipient cGMP. These standards promote the use of independent, trained third-party auditors to assess excipient manufacturing facilities. By leveraging these trained auditors, companies can ensure compliance with both cGMP and current Good Distribution Practices (cGDP).
Established Standards and Certification Programs
Two prominent programs have emerged to guide third-party auditing of excipient suppliers:
- EXCiPACT Certification Scheme: Launched in 2012, this program is aligned with ISO 9001:2015 standards and focuses on both cGMP and cGDP for excipients. It emphasizes auditor competency and the independence of certification bodies.
- NSF Health Sciences Excipient Certification Program (NSF-ECP): Initiated in 2015, this program certifies excipient manufacturers against the NSF/IPEC/ANSI 363 standard. It is accessible to all excipient manufacturers, regardless of their ISO certification status.
These certification programs aim to provide a structured approach for evaluating excipient suppliers, ensuring adherence to cGMP standards while promoting transparency and integrity in the auditing process.
The Importance of Independent Audits
Third-party certifications offer a robust alternative to traditional audits conducted by pharmaceutical companies. Unlike company-specific audits, which may be influenced by internal biases, third-party audits provide an unbiased assessment of compliance with cGMP standards. These certifications require extensive evaluation periods and ongoing surveillance to maintain validity, offering a more reliable means of assurance.
Regulatory Acceptance and Global Practices
The acceptance of third-party audits by regulatory bodies is not a novel concept. Over the years, the FDA and other global regulatory authorities have embraced the use of independent audits to ensure compliance across various sectors, including medical devices and food safety. Such recognition underscores the value of third-party certifications in bolstering quality assurance frameworks.
Best Practices for Implementing cGMP Audits
Pharmaceutical companies should actively engage with excipient suppliers to ascertain whether they possess cGMP certification. Establishing standard operating procedures (SOPs) for the acceptance of third-party audit reports can facilitate a smoother regulatory review process. However, it is essential to avoid misapplying certifications to unrelated products or grades.
Navigating Challenges and Future Directions
While third-party cGMP certifications enhance the verification of excipient quality, they do not absolve pharmaceutical companies of their responsibilities. Companies must still conduct formalized risk assessments and, in some cases, supplement audit reports with additional information. This ongoing diligence is critical for maintaining compliance and addressing any unique concerns regarding specific excipients.
- Key Takeaways:
- Pharmaceutical companies must ensure compliance with cGMP standards in excipients.
- Third-party audits provide an unbiased alternative to traditional company audits.
- Established certification programs like EXCiPACT and NSF-ECP enhance quality assurance.
- Engaging suppliers and implementing SOPs can streamline audit processes.
Conclusion
The evolution of third-party audits and certifications represents a proactive approach to ensuring that excipients meet stringent quality requirements. By adopting these practices, the pharmaceutical industry can enhance patient safety while efficiently managing the audit burden. The collaboration among stakeholders in developing these standards signifies a commitment to quality and safety that benefits all parties involved.
Read more → www.pharmtech.com
